Tevogen Bio (NASDAQ:TVGN) Trading Down 0.3% – Time to Sell?

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) fell 0.3% on Tuesday . The stock traded as low as $0.78 and last traded at $0.79. 208,679 shares were traded during trading, a decline of 62% from the average session volume of 549,448 shares. The stock had previously closed at $0.79.

Analyst Ratings Changes

Separately, D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Tevogen Bio in a research note on Thursday, September 4th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $10.00.

Tevogen Bio Stock Down 0.3%

The firm has a 50-day simple moving average of $0.91 and a 200-day simple moving average of $1.07. The stock has a market cap of $154.48 million, a PE ratio of -4.13 and a beta of -0.78.

Tevogen Bio (NASDAQ:TVGN) last released its quarterly earnings data on Tuesday, August 19th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02.

Hedge Funds Weigh In On Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. Nuveen LLC bought a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 90,253 shares of the company’s stock, valued at approximately $97,000.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.